Regeneron Pharmaceuticals
REGN · NASDAQ
Bulios Fair Price
$858.24
16.0% upside
Trenutna cena
$739.57
Po podatkih Bulios Fair Price je delnica REGN trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Regeneron Pharmaceuticals (REGN) is an American biotechnology company specializing in the development and production of drugs for the treatment of serious diseases. With a broad portfolio of medicinal products, such as Eylea and Dupixent, Regeneron Pharmaceuticals is one of the leading players in the biotechnology sector. The company is known for its emphasis on scientific research and innovation, allowing it to bring groundbreaking treatments to market. Regeneron Pharmaceuticals is also involved in partnerships with other pharmaceutical companies and academic institutions to expand its research and development capabilities. Regeneron Pharmaceuticals (REGN) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on innovation and scientific research.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Leonard S. Schleifer
Employees
15,410
Headquarters
Tarrytown
Prihajajoči dogodki
Earnings
Upcoming earnings report